Literature DB >> 16891207

Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.

Yun Gong1, Nancy Caraway, John Stewart, Gregg Staerkel.   

Abstract

We retrospectively reviewed the cytologic features of metastatic prostatic ductal carcinoma (PDC) in 23 cases, clinical manifestations, and clinical outcomes. Cytologic smears typically showed tumor cells with abundant cytoplasm and oval nuclei arranged in papillary groups or flat and folded sheets, some of which showed peripheral nuclear palisading. However, these features could be focal, subtle, and even indistinguishable from those of acinar carcinoma, particularly when the ductal component was predominantly of a cribriform and solid pattern or coexisted with acinar carcinoma. A determination of a prostatic origin of a metastatic PDC, based on cytomorphologic features alone, could be difficult. Immunostaining for prostate-specific antigen and prostatic acid phosphatase proved helpful in determining a definitive diagnosis. The median followup of patients was 82 months, the median overall survival was 77 months, and the 5-year overall survival rate was 72%. Tumor growth pattern did not correlate with prognosis, but visceral metastasis conveyed a poor prognosis. The correlation with clinical and radiologic findings, a high index of suspicion, and the use of immunoperoxidase studies are important in making an accurate diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891207     DOI: 10.1309/4TT6-LVJP-QVFW-DB6P

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.

Authors:  Qiong Gan; Cicily T Joseph; Ming Guo; Miao Zhang; Xiaoping Sun; Yun Gong
Journal:  Am J Clin Pathol       Date:  2019-09-09       Impact factor: 2.493

2.  Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.

Authors:  Aalok Kumar; Som Dave Mukherjee
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.

Authors:  Todd M Morgan; Christopher J Welty; Funda Vakar-Lopez; Daniel W Lin; Jonathan L Wright
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

4.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Authors:  Amanda H Seipel; Fredrik Wiklund; N Peter Wiklund; Lars Egevad
Journal:  Virchows Arch       Date:  2013-02-27       Impact factor: 4.064

5.  [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].

Authors:  M Brock; W Martin; F Sommerer; J Noldus
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

6.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

7.  Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate.

Authors:  Thomas N Eade; Tahseen Al-Saleem; Eric M Horwitz; Mark K Buyyounouski; David Y T Chen; Alan Pollack
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

Review 8.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

9.  Prostate cancer detection: Fusion of cytological and textural features.

Authors:  Kien Nguyen; Anil K Jain; Bikash Sabata
Journal:  J Pathol Inform       Date:  2012-01-19

10.  Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance.

Authors:  Jianjun Sha; Juanjie Bo; Jiahua Pan; Lianhua Zhang; Hanqing Xuan; Wei Chen; Dong Li; Zhaoliang Wang; Dongming Liu; Yiran Huang
Journal:  Onco Targets Ther       Date:  2013-10-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.